

---

# Tailored Therapeutics and Implications for Regulatory Endpoints – Panel Discussion

---

1. How will the FDA incorporate the use of pharmacogenomic data in treatment approvals and prescribing practices?
2. How will tailored therapeutics be implemented by the practicing oncologist?
3. What are some of the ethical consequences of tailored therapeutics and how will this impact drug discovery and delivery?

---

## Panelists

- Lawrence J. Lesko, Ph.D, FCP, Director, Office of Clinical Pharmacology , Center for Drug Evaluation and Research, FDA
  - Silvana Borges, M.D., Medical Officer, Genomics Group, Center for Drug Evaluation and Research, FDA
  - Jerome Yates, M.D., MPH, National Vice President for Research, American Cancer Society, Inc.
  - Eric M. Meslin, Ph.D., Director of the Indiana University Center for Bioethics, Professor of Medicine and Medical Genetics, IU School of Medicine
-